Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reliance On ‘Digitized Paper’ Is Slowing Drug Development – US FDA’s Woodcock

Executive Summary

Efficient development and review is being hindered by the inability to exchange data freely and truly capitalize on the digital age, CDER director says, challenging industry, regulators and others to creatively think about how to move away from legacy, paper-based processes in clinical trials and regulatory submissions.

Advertisement

Related Content

Digital Transformation Of Clinical Trials Is Shared Responsibility, CRO Industry Says
Keeping Track: US FDA Approves Novel Tetracyclines Nuzyra And Seysara; Hemlibra Indication Expands
Keeping Track: Novel Approvals For Diacomit, Takhzyro And Oxervate; CRLs For Mallinckrodt And Allergan
Keeping Track: US FDA Approvals For Tibsovo, Kisqali And Second Neupogen Biosimilar
Gottlieb Uses ASCO Platform To Unveil Two Pilot Programs To Speed Drug Review
Pharma-backed TransCelerate makes progress on clinical trial efficiency
FDA’s Woodcock Prioritizes Trial Networks As Drug Development Solution
Major Pharmas To Collaborate In Non-Profit Initiative To Resolve Clinical Development Hurdles
Expedited Approval Pathway Concept Draws Strong Support But Different Proposals
Inter-agency Cooperation

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124255

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel